AstraZeneca (LON:AZN) Rating Reiterated by Citigroup

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating reissued by equities researchers at Citigroup in a research note issued on Wednesday, MarketBeat reports. They presently have a £105 ($128.61) price objective on the biopharmaceutical company’s stock. Citigroup’s price objective points to a potential upside of 3.28% from the stock’s current price.

AZN has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a £115 ($140.86) price target on shares of AstraZeneca in a research report on Tuesday. JPMorgan Chase & Co. set a £120 ($146.99) target price on AstraZeneca in a research report on Monday, June 6th. Jefferies Financial Group set a GBX 9,500 ($116.36) target price on AstraZeneca in a research report on Friday, April 29th. UBS Group set a £101 ($123.71) target price on AstraZeneca in a research report on Tuesday, June 14th. Finally, Credit Suisse Group set a £110 ($134.74) target price on AstraZeneca in a research report on Tuesday, June 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of £105.46 ($129.17).

Shares of AZN opened at £101.67 ($124.53) on Wednesday. The company has a market cap of £157.53 billion and a PE ratio of -172.39. The business has a fifty day moving average of £103.29 and a 200 day moving average of GBX 9,441.25. AstraZeneca has a 52-week low of GBX 8,029 ($98.35) and a 52-week high of £110 ($134.74). The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 90.06.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.